You are here:

opicapone (Ongentys)

Advice

in the absence of a submission from the holder of the marketing authorisation:

opicapone (Ongentys®) is not recommended for use within NHS Scotland.

Indication under review: Adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: opicapone (Ongentys)
SMC Drug ID: 1281/17
Manufacturer: Bial Pharma UK Ltd
Indication: Adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 9 October 2017

Back